Alkem Laboratories Ltd. announced that its wholly-owned subsidiary, Alkem Medtech, has offered to acquire between 51% and 55% of the equity share capital of Swiss firm Occlutech Holding AG. This Proposed Acquisition targets entry into the advanced cardiovascular devices segment. The deal values Occlutech at a total equity value of EUR 180.70 million. Completion is targeted by June 30, 2026, subject to customary closing conditions.
Strategic Move into Advanced Cardiovascular Devices
Alkem Laboratories Ltd. disclosed that its subsidiary, M/s. Alkem Medtech Private Limited, has submitted a Binding Offer on February 13, 2026, to acquire a controlling stake in M/s. Occlutech Holding AG (“Occlutech”). The acquisition aims to secure between 51% and up to 55% of the total issued equity share capital of Occlutech for cash consideration.
This Proposed Acquisition is highly strategic, enabling Alkem to enter the advanced cardiovascular devices business segment through its subsidiary. Occlutech, a Swiss company established in December 2000, specializes in developing, manufacturing, and marketing minimally invasive cardiac implants used for treating congenital heart defects, stroke prevention, and heart failure. The acquisition is expected to enhance Alkem’s portfolio with high-quality, globally recognized products.
Transaction Value and Timeline
The Total Equity value of Occlutech has been set at EUR 180.70 million. The acquisition is anticipated to be finalized on or before June 30, 2026, or a mutually agreed alternative date, pending the satisfaction of closing conditions.
The transaction is not classified as a related party transaction, and the promoters of Alkem Laboratories have no existing interest in Occlutech.
Occlutech Financial Snapshot (2024)
Key financial data for the target entity, Occlutech, for the period ending December 31, 2024, is provided below (using an exchange rate of EUR/INR 89.20 for closing rate):
- Turnover: EUR 43.95 Million (INR 397.80 Cr)
- PAT: EUR Loss 20.52 Million (Loss INR 185.73 Cr)
- Networth (as of Dec 31, 2024): Negative EUR 3.58 Million (Negative INR 31.93 Cr)
Estimated projections for the period ending December 31, 2025 (using an average exchange rate of 98.80) are:
- Turnover: EUR 49.38 Million (INR 487.87 Cr)
- EBITDA: EUR 2.10 Million (INR 20.79 Cr)
- PAT: Loss EUR 6.85 Million (Loss INR 67.65 Cr)
Historical Performance and Global Reach
Occlutech has shown consistent growth in revenue over the past three fiscal years:
- FY 2022: Turnover EUR 31.84 Mn (INR 263.41 Cr)
- FY 2023: Turnover EUR 36.24 Mn (INR 324.28 Cr)
- FY 2024: Turnover EUR 43.95 Mn (INR 397.80 Cr)
The company maintains a global presence, deriving revenue from geographies including Germany, France, Italy, the United Kingdom, Spain, Japan, and a recent entry into the United States of America. The industry classification for the acquired entity is Healthcare (Medical device).
Regulatory Clearances
The completion of the acquisition is contingent upon securing necessary foreign direct investment clearances in both Italy and Sweden, alongside a precautionary filing in France.
Source: BSE
